Volume 2 (2015): Issue 1

The impending medical revolution in haemophilia care: one patient’s view

Open Access | | Creative Commons Attribution NonCommercial NoDerivatives
Adam R Jones

Abstract

Abstract

The history of haemophilia care has been fraught with extreme successes and epic failures. The development of plasmaderived concentrates made prophylactic treatment and home care possible, but the unintended consequences were devastating for a generation and only abated with the emergence of recombinant products. Now with the arrival of longer-acting factor concentrates and the potential offered by gene therapy, further improvements in medical and social outcomes are possible. But these new treatment approaches raise challenging ethical and moral issues that society must be prepared to confront.

Article

View Full Article

References

  • 1. Biggs R, Douglas AS, Macfarlane RC, et al. Christmas Disease. BMJ 1952; 2: 1378. doi: http://dx.doi.org/10.1136/bmj.2.4799.1378
  • 2. Darby SC, Ewart DW, Giangrande PF, et al. Mortality before and after HIV infection in the complete UK population of haemophiliacs. Nature 1995; 377: 79-82. doi:10.1038/377079a0
  • 3. Department of Health. Government response to Lord Archer’s Independent report on NHS supplied contaminated blood and blood products. London: Stationary Office; 20 May 2009
  • 4. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360(7): 692-8. doi: 10.1056/NEJMoa0802905.
  • 5. Roth DA, Kessler CM, Pasi KJ, et al; Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98(13): 3600-6.
  • 6. Zaman SM, Hill FG, Palmer B, Millar CM, Bone A, Molesworth AM, et al. The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products. Haemophilia. 2011; 17(6): 931-7. doi: 10.1111/j.1365-2516.2011.02508.x.
  • 7. Miguelino MG, Powell JS. Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B. Patient Prefer Adherence 2014; 8: 1073-83. doi: 10.2147/PPA.S54951.
  • 8. United States of America Food and Drug Administration. FDA approves first long-acting recombinant coagulation Factor IX concentrate for patients with Hemophilia B. [Online] Available from: URL http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm391037.htm (Last accessed 12/12/2014).
  • 9. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12: (Suppl. 3), 117–121.
  • 10. Cancio MI, Reiss UM, Nathwani AC, et al. Developments in the treatment of hemophilia B: focus on emerging gene therapy. Appl Clin Genet 2013; 6: 91-101. doi: 10.2147/TACG.S31928.
  • 11. High KH, Nathwani A, Spencer T, Lillicrap D. Current status of haemophilia gene therapy. Haemophilia 2014; 20 Suppl 4: 43-9. doi: 10.1111/hae.12411.
  • 12. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-65. doi: 10.1056/NEJMoa1108046.
  • 13. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994-2004. doi: 10.1056/NEJMoa1407309.
  • 14. High KA, Theodore E. Woodward Award. AAV-mediated gene transfer for haemophilia. Trans Am Clin Climatol Assoc 2003; 114: 337–352.
  • 15. World Federation of Hemophilia. [Online]. Annual Global Survey. Available from: URL http://www.wfh.org/en/resources/annual-global-survey (Last accessed 12/12/2014).

PDF Download

Download PDF

Open in full-page viewer

Authors

  • Adam R Jones

    adam.r.jones@sunderland.ac.uk
    Senior Lecturer, Department of Pharmacy, Health & Wellbeing, Faculty of Applied Science, Sciences Complex, City Campus, University of Sunderland, Sunderland, Tyne & Wear, SR1 3SD, UK